A U.S. cannabis company has made a bid to acquire Aurora Cannabis Inc., based in Edmonton. Aurora has formed a special committee to review the unsolicited offer from Curaleaf Holdings Inc., which aims to purchase all shares of the company. If successful, the acquisition would result in a combined cannabis enterprise operating in 17 countries across Europe, North America, and other global markets.
Curaleaf, headquartered in Stamford, Conn., disclosed its intention to acquire Aurora publicly after private negotiations with Aurora’s leadership failed. Although Curaleaf sent formal proposals to Aurora on June 23 and July 7, Aurora disputed Curaleaf’s claim that it declined engagement. Aurora stated that its lead independent director had communicated with Curaleaf’s CEO as recently as July 24 to discuss the proposal.
Curaleaf has proposed a payment of $4 US per share to Aurora shareholders, along with an additional $0.75 US cash for each Aurora share. Aurora has acknowledged the receipt of the proposals but emphasized that the financial terms were only detailed in the July 7 letter. However, Aurora emphasized that it did not discourage ongoing discussions with Curaleaf and will establish a special committee to evaluate the offer’s merits.
While noting Curaleaf’s interest in the acquisition positively, analysts caution that the current offer undervalues Aurora’s long-term potential. TD Cowen analysts highlighted Aurora’s market leadership in medical cannabis, diverse product portfolio, strong financial standing, and adeptness in navigating international regulations as factors contributing to its long-term value.
Curaleaf believes that merging with Aurora would leverage its global distribution network with Aurora’s established international medical cannabis operations and production capabilities. The combined revenue of the two companies exceeded $1.5 billion US over the past year, with Curaleaf anticipating annual cost synergies of at least $40 million US post-acquisition. Curaleaf sees the potential merger as beneficial for both sets of shareholders, offering an expanded global presence and increased exposure to favorable U.S. regulatory trends.
